Kathleen P. Gallagher net worth and biography

Kathleen Gallagher Biography and Net Worth

Insider of Avidity Biosciences

Kathleen Gallagher joined Avidity Biosciences in April 2021 and serves as Chief Program Officer. She previously held the roles of Senior Vice President and Global Program Head, Myotonic Dystrophy Type 1 (DM1) and Senior Vice President of Corporate Communications and Investor Relations. Ms. Gallagher brings more than 20 years of experience in the biopharmaceutical industry leading communications and investor relations in preclinical to commercial stage companies. Prior to joining Avidity, she was Vice President, Investor Relations and Corporate Communications at Akcea Therapeutics (acquired by Ionis Pharmaceuticals), where her communications strategy and relationship building expertise were essential through the development and commercial launches of rare disease therapies Tegsedi® and Waylivra®. Previously, she held roles of increasing responsibility during her 13-year tenure at Merrimack Pharmaceuticals, where she provided leadership and direction through multiple financing rounds including an IPO and through the launch of the pancreatic cancer therapy ONIVYDE®. Ms. Gallagher earned her B.S. degree in English from Boston University.

What is Kathleen P. Gallagher's net worth?: The estimated net worth of Kathleen P. Gallagher is at least $1.62 million as of February 3rd, 2025. Ms. Gallagher owns 50,554 shares of Avidity Biosciences stock worth more than $1,619,245 as of March 26th. This net worth evaluation does not reflect any other investments that Ms. Gallagher may own. Learn More about Kathleen P. Gallagher's net worth.
How do I contact Kathleen P. Gallagher?: The corporate mailing address for Ms. Gallagher and other Avidity Biosciences executives is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. Avidity Biosciences can also be reached via phone at 858-401-7900 and via email at amy@juniper-point.com. Learn More on Kathleen P. Gallagher's contact information.
Has Kathleen P. Gallagher been buying or selling shares of Avidity Biosciences?: Within the last three months, Kathleen P. Gallagher has sold $188,940.00 in shares of Avidity Biosciences stock. Most recently, Kathleen P. Gallagher sold 5,875 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $32.16, for a transaction totalling $188,940.00. Following the completion of the sale, the insider now directly owns 50,554 shares of the company's stock, valued at $1,625,816.64. Learn More on Kathleen P. Gallagher's trading history.
Who are Avidity Biosciences' active insiders?: Avidity Biosciences' insider roster includes Sarah Boyce (President & CEO), W. Flanagan (Insider), Kathleen Gallagher (Insider), Steven Hughes (Insider), Arthur Levin (Insider), Michael MacLean (Chief Financial and Chief Business Officer), Teresa Mccarthy (Insider), and Tamar Thompson (Director). Learn More on Avidity Biosciences' active insiders.
Are insiders buying or selling shares of Avidity Biosciences?: During the last year, insiders at the biotechnology company sold shares 36 times. They sold a total of 869,535 shares worth more than $31,566,515.23. The most recent insider tranaction occured on March, 20th when insider Steven George Hughes sold 9,578 shares worth more than $297,492.68. Insiders at Avidity Biosciences own 3.7% of the company. Learn More about insider trades at Avidity Biosciences.
Information on this page was last updated on 3/20/2025.

Kathleen P. Gallagher Insider Trading History at Avidity Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/3/2025	Sell	5,875	$32.16	$188,940.00	50,554

Kathleen P. Gallagher Buying and Selling Activity at Avidity Biosciences

Avidity Biosciences Company Overview

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $32.05

$31.73

$32.75

50 Day Range

MA: $31.31

$27.87

$35.11

2 Week Range

Now: $32.05

$21.56

$56.00

Volume

1,576,969 shs

Average Volume

1,354,912 shs

Market Capitalization

$3.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02